News for vTv Therapeutics Inc. (VTVT)

vTv Therapeutics (VTVT) has announced the immediate appointment of Dr. Michael Tung as Executive Vice President and Chief Financial Officer. With two decades of

vTv Therapeutics (VTVT) has appointed Michael Tung, M.D., MBA, as Executive Vice President and Chief Financial Officer. The company has reinitiated its

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. ( VTVT), a late-stage biopharmaceutical company, today announced the appointment of M

vTv Therapeutics (VTVT) is progressing with its late-stage development of cadisegliatin, which holds the potential to become the first oral adjunct treatment fo

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H

Net Loss: Reported a net loss of $5.1 million for Q1 2025, compared to a net loss of $4.9 million in the same period last year.Earnings Per Share (EPS): EPS wa

vTv Therapeutics (VTVT) reinitiates screening for CATT1 Phase 3 trial, reducing trial duration from 12 to 6 months. Cadisegliatin grante

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

**media[572530]**

Cash Position: Increased to $36.7 million as of December 31, 2024, from $9.4 million the previous year, primarily due to private placement financing and ATM Of

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protoco

vTv Therapeutics said that the U.S. FDA has lifted the clinical hold on the cadisegliatin clinical program, including late stage trial for oral treatment of type 1 diabetes. Read more here.

North Carolina-based Chimerix, Inc. (CMRX) is up over 163 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

PR NewswireWESTON, Fla., Dec. 9, 2024 WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focu

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. ( VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small

**media[481348]**

On November 18, 2024, Paul Sekhri, President, Chief Executive Officer, and Executive Chairperson of vTv Therapeutics Inc, purchased 5,000 shares of the company.

vTv Therapeutics ends key license agreement with OnKure